<DOC>
	<DOCNO>NCT02891538</DOCNO>
	<brief_summary>This randomize , control pilot trial patient histological documentation primary colon rectal adenocarcinoma resectable cancer , receive treatment cancer . If patient candidate surgical resection , plan neoadjuvant chemotherapy , patient eligible . All eligible subject consent prior surgery .</brief_summary>
	<brief_title>Chemopreventive Effects Epigallocatechin Gallate ( EGCG ) Colorectal Cancer ( CRC ) Patients</brief_title>
	<detailed_description>Part 1 : Blood draw prior surgery , follow surgical resection , surgical pathologic specimen archive . After surgery , patient see 4-12 week determine adjuvant chemotherapy indicate , case patient receive adjuvant therapy . At visit blood draw do . Part 2 : If patient stage 0/1/2 plan adjuvant treatment , patient randomize 2:1 manner EGCG 900 mg daily v observation ( standard care ) 1 year . Patients randomize EGCG arm , start EGCG within 4-12 week surgery take EGCG 450 mg PO twice day . Blood draw do 0 , 3 , 6 , 9 , 12 , 15 , 18 month . Colonoscopy do 1 year diagnosis , time normal colonic tissue biopsy well resect polyp collect .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Epigallocatechin gallate</mesh_term>
	<criteria>Cytologically histologically confirm primary colon rectal adenocarcinoma resectable cancer , receive treatment cancer . Age 18 year Eastern Cooperative Oncology Group ( ECOG ) performance status 02 The patient candidate surgical resection , plan neoadjuvant chemotherapy , plan surgery primary colorectal cancer . For woman postmenopausal ( 12 month amenorrhea ) surgically sterile ( absence ovary and/or uterus ) : agreement use two adequate method contraception . For men : agreement use barrier method contraception treatment period Hematologic , Biochemical , Organ Function within 7 day prior Cycle 1 Day 1 : Granulocyte count &gt; 1000/mm3 , Platelet count &gt; 50,000/ mm3 , Hemoglobin &gt; 7 g/dL ; Total bilirubin &lt; 2.0 ; Albumin &gt; 2.8g/dl ; aspartate aminotransferase ( AST ) ( SGOT ) alanine aminotransferase ( ALT ) ( SGPT ) &lt; 5 x upper limit normal ( ULN ) ; Serum creatinine &lt; 2 x ULN Patients receive prior chemotherapy . Patients metastatic disease . Patients may receive investigational agent . History allergic reaction attribute compound similar chemical biologic composition green tea EGCG . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Gastrointestinal tract disease result inability take oral medication requirement IV alimentation , prior surgical procedure affect absorption , active peptic ulcer disease . Patients nasogastric tube ( NGtube ) , Jtube , Gtube allow participate . Pregnant woman exclude study unknown effect EGCG teratogenic abortifacient effect . For reason , woman childbearing potential men must also agree use adequate contraception ( hormonal barrier method birth control ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Because unknown potential risk adverse event nurse infant secondary treatment mother EGCG , breastfeed discontinue . Informed Consent No study specific procedure perform without write sign informed consent document . Patients demonstrate ability understand willingness sign write informed consent document exclude study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>EGCG</keyword>
	<keyword>Green Tea</keyword>
	<keyword>Colon Cancer</keyword>
</DOC>